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Fecalmicrobiota transplantation (FMT) is an effective treatment for recurrentClostridiumdifficile infection (CDI) and is considered
as a treatment for other gastrointestinal (GI) diseases.We followed up the relief of symptoms and long-term, over-a-yearmicrobiota
stabilization in a 46-year-old man, who underwent FMT for antibiotic-induced, non-CDI colitis nine months after being treated
for CDI by FMT. Fecal and mucosal microbiota was analyzed before the second FMT and during 14 months after FMT by using
a high-throughput phylogenetic microarray. FMT resolved the symptoms and restored normal GI-function. Microbiota analysis
revealed increased bacterial diversity in the rectal mucosa and a stable fecal microbiota up to three months after FMT. A number
of mucosa-associated bacteria increased after FMT and some of these bacteria remained increased in feces up to 14 months.
Notably, the increased bacteria included Bifidobacterium spp. and various representatives of Clostridium clusters IV and XIVa,
such as Clostridium leptum, Oscillospira guillermondii, Sporobacter termitidis, Anaerotruncus colihominis, Ruminococcus callidus,
R. bromii, Lachnospira pectinoschiza, and C. colinum, which are presumed to be anti-inflammatory. The presented case suggests a
possible role of microbiota in restoring and maintaining normal GI-functionality and improves our knowledge on the etiology of
antibiotic-induced, noninfectious colitis.
1. Introduction
The intestinal tract harbors an extremely diverse micro-
biota, which is crucial in maintaining immunological and
physiological homeostasis of the mucosa [1]. Dysbiosis of
microbiota (aberrant composition) can lead to loss of nor-
mal, regulatory immune effects in the gut mucosa, and
dysbiotic microbiota has been associated with a number
of inflammatory and immune-mediated diseases [2, 3]. A
recent hypothesis presents that, after epithelial insult by
a pathogen or an injury, specific symbiotic bacteria are
needed to restore mucosal homeostasis back to a basal level
by ceasing the acute inflammation [3]. In support of the
hypothesis, a community of 17 intestinal strains attenuated
intestinal inflammation by stimulating regulatory T cells in
a mouse colitis model [4]. Fecal microbiota transplantation
(FMT) is effective in treating recurrent Clostridium difficile
infection (CDI) [5, 6], and it is increasingly considered also
for the treatment of noninfectious colitis [7]. This report
describes treatment of antibiotic-induced, noninfectious coli-
tis by FMTninemonths after the first FMT treatment for CDI
and the stabilization of intestinal microbiota in a 46-year-old
man during 14 months after the second FMT.
2. Materials and Methods
2.1.TheCase Presentation. Thepatientwas a 46-year-oldman
with history of hypertension and ventricular extrasystolia,
which were being controlled by medication. He had no
known allergies, and he had travelled only inWestern Europe.
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Figure 1: Microbiota composition at the phylum level and bacterial genus level enterotype (ET) status before FMT and during the 14-month
follow-up period.
He smoked. He had had several sinusitis episodes. Two years
before the onset of refractory Clostridium difficile infection,
he had septic infection due to the axillar bursitis. His uncle
has Crohn’s disease.
The patient hadClostridium difficile infection (CDI), after
amoxicillin clavulanate treatment for otitis media. CDI was
verified by cultivation of C. difficile and positive toxin test of
feces (VIDAS C. difficile Toxin A & B CDAB, BioMerieux,
France). No resolution of symptoms was achieved with oral
metronidazole (400mg thrice a day) or vancomycin (first
120mg four times a day and later 250mg four times a
day). Because of refractory situation, patient was hospitalized
and the treatment was switched to meropenem (1 g thrice
a day intravenously) and rifaximin (400mg twice a day).
In addition, he got one dose of immunoglobulin 27.5 g
intravenously. After six days of treatment, the patient was
discharged with ten days of rifaximin (400mg twice a day)
treatment. Three days after stopping the rifaximin treatment,
the symptoms reappeared including 10 diarrhea episodes per
day. The patient restarted rifaximin treatment and continued
it until colonoscopy and FMT were done three weeks later.
Mild nonspecific proctitis was found in colonoscopy. The
histology showed postinfectious inflammation and no typical
signs of chronic inflammatory bowel disease. FMT was
performed by infusing fecal suspension into the caecum.The
diarrhea disappeared within two days after FMT.
Seven months after FMT, the patient got clarithromycin
for sinusitis and diarrhea reappeared. Symptoms were not
as severe as earlier; that is, he had 5-6 diarrhea episodes
per day and urgency of defecation. No C. difficile or toxins
were found in feces by cultivation or toxin tests, respec-
tively. The symptoms did not resolve spontaneously during 8
weeks after the cessation of clarithromycin. Colonoscopy was
reassessed to exclude chronic inflammatory bowel disease.
The macroscopic and microscopic findings were similar as
seen previously, that is, mild inflammation. Fecal calprotectin
was also tested and was 12 𝜇g/g. The patient received the
second FMT and thereafter he has had no GI-symptoms
(two and a half years by the time of submitting this report).
The patient had three antibiotic courses during the follow-up
period between 10 and 12 months after the second FMT.
2.2. The Donor and Fecal Microbiota Transplantation (FMT).
The donor of fecal material in both transplantations was the
patient’s 35-year-old wife, whowas pregnant at the time of the
second FMT. She had not received antimicrobial therapy for
the past 6 months and did not have any intestinal symptoms.
She was tested by the protocol for fecal donors as described
previously [5]. Thirty grams of the donor’s feces were sus-
pended into 150mL of tap water and the suspension was
infused into the caecum through colonoscopy as described
previously [5].
2.3. Samples and Microbiota Analysis. Rectal biopsies were
taken from the patient at the time of the second FMT and
one month later in proctoscopy and stored in −80∘C until
further processing. The patient and donor collected fecal
samples after the second FMT according to the sampling
scheme presented in Figure 1. The fecal samples were placed
in a home freezer at −20∘C immediately after defecation and
stored in the home freezer for maximally 4 months until
transfer to laboratory for further analysis. Six healthy adult
volunteers (3 males and 3 females, mean age 67 years), who
underwent diagnostic colonoscopy and were found to have
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Figure 2: Stability of the fecal microbiota determined as Pearson
correlation of the microbiota profiles between the subsequent
sampling points.
a healthy intestine, were included as a comparison group
for mucosa-associated microbiota. DNA extraction was done
as described previously by using mechanical disruption of
bacterial cells by bead-beating followed by DNA purification
[8].Microbiota analysis was done by using theHITChip high-
throughput bacterial phylogenetic microarray as described
previously [8–11].
2.4. Ethical Considerations. The study was approved by the
Ethics Committee of Hospital District of Helsinki and Uusi-
maa (HUS), Finland (DnroHUS 124/13/03/01/11).The patient
was informed about the experimental nature and possible
risks of FMT. Written informed consent was obtained from
the patient and donor for publication of this case report. The
healthy volunteers who donated biopsies signed informed
consent.
3. Results
3.1. Resolution of GI-Symptoms by FMT. The patient’s recur-
rent Clostridium difficile infection was successfully treated by
FMT. Seven months later, he got antibiotic-induced diarrhea,
which was not as severe as earlier. Also, no C. difficile or
toxins were found in feces. The symptoms did not resolve
spontaneously within eight weeks after stopping the antibi-
otic. Colonoscopy excluded inflammatory bowel disease, but
mild inflammation was observed. The patient received FMT
again and the GI-symptoms were resolved within few days.
The patient had three antibiotic courses during the follow-up
period between 10 and 12 months after the second FMT, but
these antibiotic treatments did not induce diarrhea.
3.2. Fecal Microbiota of the Donor. In general, fecal micro-
biota of the donor was found to be stable during the 14-
month follow-up period, but a decrease in stability was
observed between 2-day and 2-week and 4- and 7-month
samples, that is, approximately one month before and three
months after the delivery, respectively (Figure 2). The most
predominating phylum was Firmicutes, where Clostridium
clusters IV and XIVa and uncultured Clostridiales were the
largest groups (Figure 1). Phylum Bacteroidetes constituted
2–13% and Actinobacteria and Proteobacteria less than 4% of
the total microbiota in the donor (Figure 1). In the enterotype
(ET) profiling, the donor’s fecal microbiota represented
ET3, that is, the Ruminococcus enterotype (Figure 1). The
diversity and richness of fecal microbiota were higher in the
donor than in the patient throughout the follow-up period
(Figure 3).
3.3. Mucosal and Fecal Microbiota of the Patient during 14
Months after the FMT. Intestinal microbiota composition
was followed up with frequent sampling during 14 months
after the FMT. In the patient, a shift from a Bacteroidetes-rich
fecal microbiota to a microbiota, where Firmicutes constitute
over 87% of the bacterial community, was observed from two
weeks after FMT onwards (Figure 1). Particularly, the relative
proportion of Clostridium cluster XIVa increased by 20%
in feces after FMT. However, in mucosa, the relative abun-
dance of the phylum Bacteroidetes increased and Firmicutes
decreased after FMT. Fecal microbiota two days after FMT
resembled the pre-FMTmicrobiota and may reflect an adap-
tation stage. Also, fecal microbiota enterotype (ET) profiling
analysis showed a shift at 2 days after FMT. Fecal microbiota
represented enterotype 3 (ET3), that is, the Ruminococcus
enterotype at all other sampling points except at 2 days after
FMT. In contrast,mucosalmicrobiota represented enterotype
2 (ET2), that is, the Prevotella enterotype (Figure 1). Consis-
tently, both the phylum level and enterotype profiling, that is,
genus level analysis, showed that the composition of mucosa-
associated microbiota is different from that of the fecal
microbiota. The patient’s fecal microbiota was stable from 2
weeks to 3 months after FMT, but then stability decreased
slightly between 3 and 7 months and more notably between 7
and 14months (Figure 2). From 7- to 14-month fecal samples,
a shift back to a Bacteroidetes-rich fecal microbiota was seen
(Figure 1). The shift cooccurred with the administration of
three antibiotic courses between these sampling points.
Further, the analysis of mucosa-associated microbiota
revealed a marked increase in the diversity and richness
of bacterial species in post-FMT rectal biopsy as compared
to the pre-FMT biopsy (Figure 3). The increase in diversity
and richness in the patient’s rectal mucosa exceeded the
interindividual variability of rectal biopsies from six healthy
controls (Figure 3). The increase in diversity also exceeded
intraindividual variability between ileal and rectal biopsies
from the same individual (Figure 3). The results indicate
that the increase in diversity and richness of the patient’s
mucosal microbiota is beyond the natural variability. Thus,
the mucosal microbiota of the patient seemed to be strongly
affected by FMT. However, in the luminal contents (feces),
the increase in bacterial diversity and richness was modest
(Figure 3). Interestingly, the post-FMT biopsy of the patient
clustered with fecal samples of the donor in hierarchical
clustering of themicrobiota profiles (Supplementary Figure 1
available online at http://dx.doi.org/10.1155/2014/913867). A
number of bacterial groups in the mucosa showed either
a decrease or an increase in their relative abundance after
FMT (Table 1). Most of these bacterial groups (46 out of 49)
showed a similar difference between the donor and the pre-
FMT patient fecal samples. Further, specific bacterial groups
in post-FMT mucosal sample showed the same direction
of change in their relative abundance in the fecal sample
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Table 1: Mucosal bacteria with >2-fold change in relative abundance after FMT and constituting >0.01% of the microbiota.
Phylum/cluster Increased bacterial groupsin colonic mucosa1
Fold-change
B0 to B1
Increased in feces
F14m and F2w–7m3
Actinobacteria Bifidobacterium spp. 2.2 Yes
Bacteroidetes Prevotella melaninogenica et rel. 5.6 NoPrevotella oralis et rel. 5.7 No
Firmicutes/Clostridium cl. IV
Clostridium leptum et rel. 2.5 Yes
Oscillospira guillermondii et rel. 4.8 Yes
Sporobacter termitidis et rel. 2.7 Yes
Anaerotruncus colihominis et rel. 3.4 Yes
Ruminococcus callidus et rel. 4.1 Yes
Ruminococcus lactaris et rel. 15.4 No
Ruminococcus bromii et rel. 12.0 Yes
Subdoligranulum variabile et rel. 7.9 No
Firmicutes/Clostridium cl. IX Dialister spp. 3.6 Yes
Firmicutes/Clostridium cl. XIVa
Lachnospira pectinoschiza et rel. 2.3 Yes
Ruminococcus lactaris et rel. 15.4 No
Butyrivibrio crossotus et rel. 2.5 No
Clostridium colinum et rel. 3.3 Yes
Uncult. Clostridiales Uncult. ClostridialesI 10.2 Yes
Proteobacteria Oxalobacter formigenes 3.5 Yes
Phylum/cluster Decreased bacterial groupsin colonic mucosa2
Fold-change
B0 to B1
Decreased in feces
F14m and F2w–7m3
Bacteroidetes
Alistipes et rel. 2.0 No
Bacteroides stercoris et rel. 2.4 No
Bacteroides vulgatus et rel. 9.6 Yes
Bacteroides fragilis et rel. 2.1 Yes
Bacteroides ovatus et rel. 3.4 Yes
Bacteroides intestinalis et rel. 3.4 No
Bacteroides plebeius et rel. 2.5 No
Prevotella tannerae et rel. 6.2 Yes
Tannerella et rel. 2.4 No
Parabacteroides distasonis et rel. 4.0 No
Uncult. Bacteroidetes 5.9 No
Firmicutes/Clostridium cl. I Clostridia 5.8 No
Firmicutes/Clostridium cl. XIVa
Coprococcus eutactus et rel. 2.4 No
Dorea formicigenerans et rel. 4.0 No
Eubacterium rectale et rel. 2.0 No
Ruminococcus gnavus et rel. 7.0 No
Ruminococcus obeum et rel. 4.4 No
Clostridium nexile et rel. 5.3 No
Outgr. Clostridium cl. XIVa 6.2 No
Firmicutes/Clostridium cl. IX Veillonella spp. 2.7 NoMegasphaera elsdenii et rel. 3.4 No
Firmicutes/Clostridium cl. XI Clostridium difficile et rel. 23.1 No
Firmicutes/Clostridium cl. XVI Bulleidia moorei et rel. 2.1 NoEubacterium cylindroides et rel. 2.2 No
Firmicutes/Clostridium cl. XVIII Clostridium ramosum et rel. 8.1 Yes
Firmicutes/Bacilli
Streptococcus bovis et rel. 2.3 No
Streptococcus intermedius et rel. 2.3 No
Streptococcus mitis et rel. 2.1 No
Proteobacteria
Sutterella wadsworthia et rel. 2.7 No
Escherichia coli et rel. 3.7 No
Klebsiella pneumonia et rel. 2.2 No
1Higher abundance also in the donor’s feces as compared to the patient’s pre-FMT feces; 2lower abundance also in the donor’s feces as compared to the patient’s
pre-FMT feces, with the exception ofC. eutactus et rel., E. rectale et rel., and S. bovis et rel.; 3increased/decreased abundance in 14mo and in 2w to 7mo (average)
post-FMT samples as compared to the pre-FMT fecal sample; Uncult.: uncultured; cl.: cluster; Outgr.: outgrouping.
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Figure 3: Diversity and richness of microbiota in the fecal samples (a and c) and inmucosal biopsies from the patient and six healthy controls
(b and d). 0 d: pre-FMT sample; 2 wk to 14mo: post-FMT samples. Line connects the rectal and ileal samples from the same individual.
at 14months after FMT and during the follow-up period from
2 weeks to 7 months (in average) as compared to the pre-
FMT feces (Table 1). The increased bacterial groups include
Bifidobacterium spp. (Actinobacteria), Clostridium leptum et
rel., Oscillospira guillermondii et rel., Sporobacter termitidis et
rel., Anaerotruncus colihominis et rel., Ruminococcus callidus
et rel., R. bromii et rel. (Clostridium cluster IV), Dialister
spp. (Clostridium cluster IX), Lachnospira pectinoschiza et
rel., C. colinum et rel. (Clostridium cluster XIVa), uncultured
Clostridiales I, andOxalobacter formigenes et rel. (Proteobac-
teria) (Table 1). We assume that these bacterial groups have
established themselves stably from the donor’s microbiota
or have successfully and stably recovered from the patient’s
own microbiota after FMT. On the other hand, four groups
belonging to Bacteroidetes and Clostridium ramosum et rel.
(Clostridium cluster XVIII) decreased after FMT both in
mucosa and in feces.
4. Discussion
The case described herein presents an expansion of the use
of FMT to treat antibiotic-induced, non-CDI colitis. FMT
restored normal GI-function and the patient has not had GI-
symptoms thereafter, that is, two and a half years at the time
of writing this report.
Interestingly, the patient did not seem to have perturbed
fecal microbiota prior to FMT. The relative proportion of
Bacteroidetes was rather high, but within the normal vari-
ation in healthy Europeans adults [9]. Also, the microbiota
composition of the donorwas typical to healthy adults [9] and
showed high stability during the last month of pregnancy and
three months postpartum, which is in line with the results
from a recent study [12]. In the patient, the proportion of
Bacteroidetes still increased two days after the FMT, but
later a clear shift to a Firmicutes-dominating microbiota was
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observed. It seems that a period ranging from few days to
two weeks is needed before the establishment of post-FMT
microbiota.The temporary shift of the microbiota enterotype
at 2d after FMT also indicates a transition period. At the
phylum level, fecal microbiota was relatively stable from
two weeks up to three months after FMT. Recently, a stable
phylum level microbiota composition was reported in three
patients, who were followed up for 3-4 months after FMT for
recurrentC. difficile infection [13]. In our patient, the diversity
of microbiota decreased and the total microbiota was less
stable after three months after FMT. The result indicates that
microbiota evolution may continue for a considerable period
of time after FMT and underlines the need for long-term
post-FMT follow-up studies of microbiota stabilization.
In the patient, fecal and mucosal microbiota showed
different compositions at both bacterial phylum and genus
levels. In the enterotype profiling, fecal microbiota was found
to be enterotype 3 (ET3) and mucosal microbiota enterotype
2 (ET2). The three enterotypes are each characterized by
a discriminating genus, Bacteroides (ET1), Prevotella (ET2),
or Ruminococcus (ET3), whose abundance correlates with
the abundance of other genera [11]. Thus, the enterotypes
are driven by groups of bacteria that together contribute
to the preferred microbiota composition, which is a result
of adaption to the particular environment. Interestingly, the
bacterial diversity and richness were higher in the mucosal
biopsies as compared to feces. Similarly, higher bacterial
richness was observed in themucosa as compared tomatched
fecal samples in a recent study comprising four individ-
uals [14]. Clearly, intestinal lumen and mucosa represent
different environments and, consequently, harbor different
microbiota.
We observed a shift back to a Bacteroidetes-rich fecal
microbiota in the patient at 14 months after FMT. The shift
was associated with the administration of three antibiotic
courses, which, however, did not induce diarrhea this time.
Thus, at the phylum level composition, the patient’s micro-
biota at 14 months resembled microbiota before FMT, but
apparently he maintained some key bacterial species that
could support gut functionality even when challenged by
antibiotics. Indeed, we observed a drastic increase in the
diversity and richness of mucosal microbiota after FMT indi-
cating either the strong engraftment of donor’s microbiota or
the recovery of patient’s own microbiota particularly in the
mucosal lining. Specific mucosa-associated bacteria, which
increased in abundance, showed an increase also in feces
up to 14 months after FMT. The increased bacterial groups
include Bifidobacterium and Dialister spp., bacteria related
to Clostridium leptum, Oscillospira guillermondii, Sporobac-
ter termitidis, Anaerotruncus colihominis, Ruminococcus cal-
lidus, R. bromii, Lachnospira pectinoschiza, C. colinum, and
Oxalobacter formigenes, as well as uncultured Clostridiales
I. We assume that these bacterial groups have established
themselves stably after FMT and may have a crucial role in
maintaining gut homeostasis. Previously, Bifidobacterium, C.
leptum, Sporobacter, Oscillospira, Anaerotruncus, R. bromii,
Dialister, and uncultured Clostridiales have been found
to be increased in healthy individuals as compared to
inflammatory bowel disease (IBD) patients [10, 15]. Further,
a combination of 17 strains of intestinal bacteria, belonging
to the generaRuminococcus,Anaerotruncus, Lachnospiraceae,
Clostridium, Eubacterium, and Blautia, has been shown to
attenuate inflammation in a mouse colitis model by stimu-
lating regulatory T cells [4]. As an exception, O. formigenes
has no reported anti-inflammatory effects but is associated
with a reduced risk of calcium oxalate stone disease [16].
Collectively, our patient showed constantly increased levels
of intestinal bacteria, which seem to have anti-inflammatory
effects and possibly ceased the mild, on-going inflammation.
In the presented case, FMT resolved the symptoms in
an antibiotic-induced, noninfectious colitis. The post-FMT
bacterial community restored normal GI-function possibly
by ceasing the mild, on-going inflammation. The micro-
biota analysis suggests that specific members of microbiota
may have a role in restoring and maintaining normal GI-
functionality. Interestingly, the 17 strains in the study by
Atarashi et al. [4] exerted an anti-inflammatory effect as
a community, but not as individual strains. Thus, it seems
that an assembly of bacterial species, rather than a specific
single species, is essential in preventing or treating intestinal
diseases. Today, FMT is the most straightforward way of
introducing the necessary combination of bacteria to a
patient, but there is an increasing need to identify the
crucial bacterial species that are able to control infection or
inflammation in the intestine. The first two cases on the use
of an “artificial stool” consisting of pure cultures of intestinal
bacterial have shown promising results in the treatment
of recurrent CDI [17]. Clinical FMT-studies linked with
microbiota analysis can greatly advance these efforts and
improve our understanding of the etiology of diseases, where
dysbiosis of the microbiota is considered to play a role.
5. Conclusions
The antibiotic-induced, noninfectious colitis of a 46-year-old
man was successfully treated with FMT.The results suggest a
possible role of intestinalmicrobiota and its specificmembers
in restoring and maintaining normal GI-functionality.
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